279 related articles for article (PubMed ID: 21163920)
1. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
[TBL] [Abstract][Full Text] [Related]
2. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
Aydin E; Hallner A; Grauers Wiktorin H; Staffas A; Hellstrand K; Martner A
Oncogene; 2019 Feb; 38(9):1534-1543. PubMed ID: 30323311
[TBL] [Abstract][Full Text] [Related]
3. Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.
Wang J; Liu Y; Tan LX; Lo JC; Du J; Ryu MJ; Ranheim EA; Zhang J
Cell Cycle; 2011 Sep; 10(17):2836-9. PubMed ID: 21857161
[TBL] [Abstract][Full Text] [Related]
4. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
[TBL] [Abstract][Full Text] [Related]
5. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
6. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
[TBL] [Abstract][Full Text] [Related]
8. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.
Wang J; Kong G; Liu Y; Du J; Chang YI; Tey SR; Zhang X; Ranheim EA; Saba-El-Leil MK; Meloche S; Damnernsawad A; Zhang J; Zhang J
Blood; 2013 Jun; 121(26):5203-7. PubMed ID: 23687087
[TBL] [Abstract][Full Text] [Related]
9. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
[TBL] [Abstract][Full Text] [Related]
10. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
Xue L; Pulikkan JA; Valk PJ; Castilla LH
Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
[TBL] [Abstract][Full Text] [Related]
11. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
[TBL] [Abstract][Full Text] [Related]
12. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.
Chan IT; Kutok JL; Williams IR; Cohen S; Kelly L; Shigematsu H; Johnson L; Akashi K; Tuveson DA; Jacks T; Gilliland DG
J Clin Invest; 2004 Feb; 113(4):528-38. PubMed ID: 14966562
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia.
Chan IT; Gilliland DG
Cell Cycle; 2004 May; 3(5):536-7. PubMed ID: 15020845
[TBL] [Abstract][Full Text] [Related]
14. Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study.
Shi X; Yang Y; Shang S; Wu S; Zhang W; Peng L; Huang T; Zhang R; Ren R; Mi J; Wang Y
BMC Cancer; 2019 Nov; 19(1):1072. PubMed ID: 31703632
[TBL] [Abstract][Full Text] [Related]
15. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.
Wolf S; Rudolph C; Morgan M; Büsche G; Salguero G; Stripecke R; Schlegelberger B; Baum C; Modlich U
Oncogene; 2013 Jun; 32(25):3028-38. PubMed ID: 22847614
[TBL] [Abstract][Full Text] [Related]
16. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice.
Zambetti NA; Firestone AJ; Remsberg JR; Huang BJ; Wong JC; Long AM; Predovic M; Suciu RM; Inguva A; Kogan SC; Haigis KM; Cravatt BF; Shannon K
Blood; 2020 May; 135(20):1772-1782. PubMed ID: 32219446
[TBL] [Abstract][Full Text] [Related]
17. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
[TBL] [Abstract][Full Text] [Related]
18. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
Braun BS; Tuveson DA; Kong N; Le DT; Kogan SC; Rozmus J; Le Beau MM; Jacks TE; Shannon KM
Proc Natl Acad Sci U S A; 2004 Jan; 101(2):597-602. PubMed ID: 14699048
[TBL] [Abstract][Full Text] [Related]
19. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.
Kong G; Wunderlich M; Yang D; Ranheim EA; Young KH; Wang J; Chang YI; Du J; Liu Y; Tey SR; Zhang X; Juckett M; Mattison R; Damnernsawad A; Zhang J; Mulloy JC; Zhang J
J Clin Invest; 2014 Jun; 124(6):2762-73. PubMed ID: 24812670
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.
Xu J; Hedberg C; Dekker FJ; Li Q; Haigis KM; Hwang E; Waldmann H; Shannon K
Blood; 2012 Jan; 119(4):1032-5. PubMed ID: 22144181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
